Wealthcare Advisory Partners’s Cytokinetics CYTK Stock Holding History

Wealthcare Advisory Partners’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-410	Closed	-$10K	–	831
2021 Q1	$10K	Buy	+410	New	+$8.76K	﹤0.01%	1443
2020 Q2	–	Sell	-410	Closed	-$5K	–	527
2020 Q1	$5K	Hold	410	–	–	﹤0.01%	1093
2019 Q4	$4K	Hold	410	–	–	﹤0.01%	1135
2019 Q3	$5K	Hold	410	–	–	﹤0.01%	1066
2019 Q2	$5K	Buy	+410	New	+$3.95K	﹤0.01%	1048

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Wealthcare Advisory Partners's CYTK Position: Q2 2021 in Review

Wealthcare Advisory Partners sold out of Cytokinetics (CYTK) in Q2 2021, closing a stake of 410 shares — an estimated $10K sold.

Wealthcare Advisory Partners first reported a position in CYTK in Q2 2019 and held it in 5 quarters. The position peaked at $10K in Q1 2021. 190 funds tracked by Wall St. Rank hold CYTK as of Q2 2021.

Wealthcare Advisory Partners reported no remaining Cytokinetics position as of Q2 2021 after selling out during the quarter.
Wealthcare Advisory Partners sold 410 Cytokinetics shares in Q2 2021, an estimated $10K.
Wealthcare Advisory Partners first reported a position in Cytokinetics in Q2 2019 and held it in 5 quarters.
Wealthcare Advisory Partners's Cytokinetics position peaked at $10K in Q1 2021.
190 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2021.

Based on Wealthcare Advisory Partners's 13F filing for Q2 2021, filed 16 Aug 2021.